211
Views
5
CrossRef citations to date
0
Altmetric
Original Article

Plasma levels of guanylins are reduced in patients with Crohn’s disease

ORCID Icon, , ORCID Icon, , ORCID Icon, , ORCID Icon, ORCID Icon & show all
Pages 449-453 | Received 27 Feb 2020, Accepted 21 Mar 2020, Published online: 20 Apr 2020

References

  • Basu N, Arshad N, Visweswariah SS. Receptor guanylyl cyclase C (GC-C): regulation and signal transduction. Mol Cell Biochem. 2010;334:67–80.
  • (a) Rao S, Lembo AJ, Shiff SJ, et al. A 12-week, randomized, controlled trial with a 4-week randomized withdrawal period to evaluate the efficacy and safety of linaclotide in irritable bowel syndrome with constipation. Am.J.Gastroenterol. 2012;107:1714–1724. (b) Dye FS, Larraufie P, Kay R, et al. Characterisation of proguanylin expressing cells in the intestine - evidence for constitutive luminal secretion. Sci Rep. 2019;9:15574.
  • Brenna O, Bruland T, Furnes MW, et al. The guanylate cyclase-C signaling pathway is down-regulated in inflammatory bowel disease. Scand.J.Gastroenterol. 2015;50:1241–1252.
  • (a) Han XN, Mann E, Gilbert S, et al. Loss of guanylyl cyclase C (GCC) signaling leads to dysfunctional intestinal barrier. Plos One. 2011;6:e16139. (b) Wu F, Zhang SM, Dassopoulos T, et al. Identification of MicroRNAs Associated with Ileal and Colonic Crohn’s Disease. Inflammatory Bowel Dis. 2010;16:1729–1738.
  • Wu F, Dassopoulos T, Cope L, et al. Genome-vide gene expression differences in Crohn’s disease and ulcerative colitis from endoscopic pinch biopsies: insights into distinctive pathogenesis. Inflammatory Bowel Dis. 2007;13:807–821.
  • Brenna O, Furnes MW, Munkvold B, et al. Cellular localization of guanylin and uroguanylin mRNAs in human and rat duodenal and colonic mucosa. Cell Tissue Res. 2016;365:331–341.
  • Forte LR. Guanylin regulatory peptides: structures, biological activities mediated by cyclic GMP and pathobiology. Regul Pept. 1999;81:25–39.
  • Brierley SM. Guanylate cyclase-C receptor activation: unexpected biology. Curr Opin Pharmacol. 2012;12:632–640.
  • (a) Moss NG, Fellner RC, Qian X, et al. Uroguanylin, an intestinal natriuretic peptide, is delivered to the kidney as an unprocessed propeptide. Endocrinology. 2008;149:4486–4498. (b) Qian X, Moss NG, Fellner RC, et al. Circulating prouroguanylin is processed to its active natriuretic form exclusively within the renal tubules. Endocrinology. 2008;149:4499–4509.
  • Wasinger VC, Yau Y, Duo X, et al. Low mass blood peptides discriminative of inflammatory bowel disease (IBD) severity: a quantitative proteomic perspective. Mol Cell Proteomics. 2016;15:256–265.
  • Fiskerstrand T, Arshad N, Haukanes BI, et al. Familial diarrhea syndrome caused by an activating GUCY2C mutation. N Engl J Med. 2012;366:1586–1595.
  • von Volkmann HL, Nylund K, Tronstad RR, et al. An activating gucy2c mutation causes impaired contractility and fluid stagnation in the small bowel. Scand J Gastroenterol. 2016;51:1308–1315.
  • von Volkmann HL, Bronstad I, Gilja OH, et al. Prolonged intestinal transit and diarrhea in patients with an activating GUCY2C mutation. PLoS One. 2017;12:e0185496.
  • Halpin SJ, Ford AC. Prevalence of symptoms meeting criteria for irritable bowel syndrome in inflammatory bowel disease: systematic review and meta-analysis. Am J Gastroenterol. 2012;107:1474–1482.
  • Dunlop SP, Jenkins D, Spiller RC. Distinctive clinical, psychological, and histological features of postinfective irritable bowel syndrome. Am J Gastroenterol. 2003;98:1578–1583.
  • Harvey RF, Bradshaw JM. A simple index of Crohn’s-disease activity. Lancet. 1980;315:514.
  • Hanevik K, Kristoffersen EK, Sornes S, et al. Immunophenotyping in post-giardiasis functional gastrointestinal disease and chronic fatigue syndrome. BMC Infect Dis. 2012;12:258.
  • (a) Hanevik K, Dizdar V, Langeland N, et al. Development of functional gastrointestinal disorders after Giardia lamblia infection. BMC Gastroenterology. 2009;9. (b) Morch K, Hanevik K, Rivenes AC, et al. Chronic fatigue syndrome 5 years after giardiasis: differential diagnoses, characteristics and natural course. BMC Gastroenterol. 2013;13:28.(c) Thompson WG, Longstreth GF, Drossman DA, et al. Functional bowel disorders and functional abdominal pain. Gut. 1999;45:Ii43–47.
  • Priyamvada S, Gomes R, Gill RK, et al. Mechanisms underlying dysregulation of electrolyte absorption in inflammatory bowel disease-associated diarrhea. Inflamm Bowel Dis. 2015;21:2926–2935.
  • Kuhn M, Kulaksiz H, Cetin Y, et al. Circulating and tissue guanylin immunoreactivity in intestinal secretory diarrhoea. Eur J Clin Invest. 1995;25:899–905.
  • Lan D, Niu J, Miao J, et al. Expression of guanylate cyclase-C, guanylin, and uroguanylin is downregulated proportionally to the ulcerative colitis disease activity index. Sci Rep. 2016;6:25034.
  • (a) Fellner RC, Moss NG, Goy MF, Dietary salt regulates uroguanylin expression and signaling activity in the kidney, but not in the intestine. Physiol Rep. 2016;4:e12782. (b) Qian X, Moss NG, Fellner RC, et al. The rat kidney contains high levels of prouroguanylin (the uroguanylin precursor) but does not express GC-C (the enteric uroguanylin receptor). Am J Physiol Renal Physiol. 2011;300:F561–573. (c) Valentino MA, Lin JE, Snook AE, et al. A uroguanylin-GUCY2C endocrine axis regulates feeding in mice. J Clin Invest. 2011;121:3578–3588.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.